Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Norberto PericoPiero RuggenentiAnnalisa PernaAnna CaroliMatias TrilliniSandro SironiAntonio PisaniEleonora RiccioMassimo ImbriacoMauro DugoGiovanni MoranaAntonio GranataMichele FigueraFlavio GaspariFabiola CarraraNadia RubisAlessandro VillaSara GambaSilvia PrandiniMonica CortinovisAndrea RemuzziGiuseppe Remuzzinull nullPublished in: PLoS medicine (2019)
ClinicalTrials.gov NCT01377246; EudraCT: 2011-000138-12.